Bloomberg "Anywhere" Remote Login Bloomberg "Terminal" Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


September 03, 2015 2:02 PM ET

Biotechnology

Company Overview of Agios Pharmaceuticals, Inc.

Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and rare genetic disorders of metabolism in the United States. The company’s product candidates include AG-221, a potent inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations; and AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations. Its product candidates also comprise AG-348, an oral small molecule and activator of the pyruvate kinase-R enzyme used for the treatment of patients with PK...

38 Sidney Street

2nd Floor

Cambridge, MA 02139

United States

Founded in 2007

128 Employees

Phone:

617-649-8600

Key Executives for Agios Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 58
Total Annual Compensation: $500.0K
Principal Financial Officer and Senior Vice President of Finance
Age: 44
Total Annual Compensation: $309.0K
Chief Operating Officer
Age: 60
Total Annual Compensation: $375.0K
Chief Medical Officer
Age: 54
Total Annual Compensation: $371.4K
Chief Scientific Officer
Age: 59
Total Annual Compensation: $387.3K
Compensation as of Fiscal Year 2014.

Agios Pharmaceuticals, Inc. Key Developments

Agios Pharmaceuticals, Inc. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Agios Pharmaceuticals, Inc. announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, collaboration revenue, related party was $13,219,000 against $8,411,000 a year ago. Loss from operations was $32,133,000 against $18,330,000 a year ago. Net loss was $31,897,000 or $0.85 per basic and diluted share against $18,296,000 or $0.54 per basic and diluted share a year ago. The increase reflects revenues recognized under the company's collaboration agreements with Celgene, including $8.8 million related to the delivery of the U.S. and ex-U.S. licenses for AG-881. For the six months, collaboration revenue, related party was $47,421,000 against $16,822,000 a year ago. Loss from operations was $37,328,000 against $30,614,000 a year ago. Net loss was $36,854,000 or $0.99 per basic and diluted share against $30,544,000 or $0.94 per basic and diluted share a year ago.

Agios Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Agios Pharmaceuticals, Inc., Q2 2015 Earnings Call, Aug 06, 2015

Agios Pharmaceuticals, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 08:30 AM

Agios Pharmaceuticals, Inc. Presents at 35th Annual Canaccord Genuity Growth Conference, Aug-12-2015 08:30 AM. Venue: InterContinental Boston, 510 Atlantic Avenue, Boston, MA 02210, United States.

Similar Private Companies By Industry

Company Name Region
MMR Life Sciences Group, Inc. United States
Nirmidas Biotech, Inc. United States
Audeo Oncology, Inc. United States
Biolight Harvesting, Inc. United States
Chelsea Therapeutics International Ltd. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Agios Pharmaceuticals, Inc., please visit www.agios.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.